Palliative Osimertinib Rechallenge Achieving Rapid Improvement in Leptomeningeal Carcinomatosis After Prior Osimertinib-Induced ILD.

A patient with EGFR-mutant lung cancer developed leptomeningeal carcinomatosis years after osimertinib-induced ILD. With no other treatment options, palliative osimertinib rechallenge led to rapid neurological improvement and radiological response, without ILD recurrence. This case highlights the potential of carefully monitored osimertinib rechallenge for symptomatic relief in exceptional cases.